At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 129 enrolled
Drug / intervention
LTB-SA7 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomized, Double-Blinded and Controlled Trial to Evaluate Safety and Immunogenicity of an Investigational Multicomponent Staphylococcus Aureus Toxoid Vaccine (LTB-SA7) in Healthy Adults.
In Brief
A Phase 1 clinical trial evaluating LTB-SA7 and Placebo for Staphylococcus (S.) Aureus Infection. Completed, enrolled 129 participants across 1 site.
Detailed Summary
In this study, the candidate vaccine LTB-SA7 will be tested for safety and immunogenicity in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStaphylococcus (S.) Aureus Infection
CountriesUnited States
Timeline
Phase 1CompletedFinished
20252026
First PostedDec 2024
Enrollment StartJan 2025
Primary CompletionMar 2026
TodayJul 2026
First PostedDec 5, 2024
Enrollment StartJan 7, 2025
Primary CompletionMar 4, 2026
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 1.6 years ago
Interventions
LTB-SA7biological
LTB-SA7 is a toxoid based vaccine consisting of five components including seven toxoids formulated with Alhydrogel.
Placebobiological
Sodium Phosphate with Sodium Chloride